About Tumor necrosis factor receptor superfamily member 19
Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) is a protein
from Homo sapiens identified by UniProt accession
Q9NS68, 423 residues long.
MolForge cross-references it against 0 known binders and
87 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 19 |
| UniProt accession | Q9NS68 |
| Gene | TNFRSF19 |
| Organism | Homo sapiens |
| Length | 423 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (87)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.51
- nasopharyngeal neoplasm · score 0.44
- blood protein measurement · score 0.40
- bone density · score 0.31
- lung carcinoma · score 0.19
- glioma · score 0.09
- hepatocellular carcinoma · score 0.08
- neoplasm · score 0.07
- oral squamous cell carcinoma · score 0.07
- non-small cell lung carcinoma · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NS68-F1 | alphafold | PREDICTED | 60.31 | — |
Amino-acid sequence (423 residues)
MALKVLLEQE KTFFTLLVLL GYLSCKVTCE SGDCRQQEFR DRSGNCVPCN QCGPGMELSK ECGFGYGEDA QCVTCRLHRF KEDWGFQKCK PCLDCAVVNR FQKANCSATS DAICGDCLPG FYRKTKLVGF QDMECVPCGD PPPPYEPHCA SKVNLVKIAS TASSPRDTAL AAVICSALAT VLLALLILCV IYCKRQFMEK KPSWSLRSQD IQYNGSELSC FDRPQLHEYA HRACCQCRRD SVQTCGPVRL LPSMCCEEAC SPNPATLGCG VHSAASLQAR NAGPAGEMVP TFFGSLTQSI CGEFSDAWPL MQNPMGGDNI SFCDSYPELT GEDIHSLNPE LESSTSLDSN SSQDLVGGAV PVQSHSENFT AATDLSRYNN TLVESASTQD ALTMRSQLDQ ESGAVIHPAT QTSLQVRQRL GSL
Explore Tumor necrosis factor receptor superfamily member 19 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets